JP2023535121A5 - - Google Patents

Info

Publication number
JP2023535121A5
JP2023535121A5 JP2022570440A JP2022570440A JP2023535121A5 JP 2023535121 A5 JP2023535121 A5 JP 2023535121A5 JP 2022570440 A JP2022570440 A JP 2022570440A JP 2022570440 A JP2022570440 A JP 2022570440A JP 2023535121 A5 JP2023535121 A5 JP 2023535121A5
Authority
JP
Japan
Prior art keywords
parkin
seq
optionally
protein
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022570440A
Other languages
English (en)
Japanese (ja)
Other versions
JP7872737B2 (ja
JP2023535121A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033491 external-priority patent/WO2021236981A2/en
Publication of JP2023535121A publication Critical patent/JP2023535121A/ja
Publication of JP2023535121A5 publication Critical patent/JP2023535121A5/ja
Application granted granted Critical
Publication of JP7872737B2 publication Critical patent/JP7872737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022570440A 2020-05-20 2021-05-20 操作されたパーキン及びその使用 Active JP7872737B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063027866P 2020-05-20 2020-05-20
US202063027868P 2020-05-20 2020-05-20
US63/027,868 2020-05-20
US63/027,866 2020-05-20
PCT/US2021/033491 WO2021236981A2 (en) 2020-05-20 2021-05-20 Engineered parkin and uses thereof

Publications (3)

Publication Number Publication Date
JP2023535121A JP2023535121A (ja) 2023-08-16
JP2023535121A5 true JP2023535121A5 (enExample) 2024-05-29
JP7872737B2 JP7872737B2 (ja) 2026-06-10

Family

ID=78707577

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570440A Active JP7872737B2 (ja) 2020-05-20 2021-05-20 操作されたパーキン及びその使用

Country Status (5)

Country Link
US (1) US20230174994A1 (enExample)
EP (1) EP4153614A4 (enExample)
JP (1) JP7872737B2 (enExample)
CA (1) CA3177341A1 (enExample)
WO (1) WO2021236981A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102673203B1 (ko) 2016-04-20 2024-06-10 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Pklr의 유전자 발현 증강을 위한 조성물 및 방법
AU2018352583B2 (en) 2017-10-16 2025-04-17 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency
US12539316B2 (en) 2018-04-11 2026-02-03 Spacecraft Seven, Llc Compositions and methods for stem cell transplant
IL278213B2 (en) 2018-04-27 2026-04-01 Rocket Pharmaceuticals Ltd A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
IL280465B2 (en) 2018-07-30 2025-03-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Methods for gene modification of hematopoietic cells
WO2022032226A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
CN119193701B (zh) * 2024-09-13 2025-07-15 暨南大学 帕金森动物模型的构建方法与特异性靶向Parkin基因的gRNA及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026116A2 (en) * 2007-08-16 2009-02-26 Genizon Biosciences, Inc. Genemap of the human genes associated with longevity
WO2011053825A2 (en) * 2009-10-30 2011-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment or prevention of mitochondrial diseases
WO2012050402A2 (ko) * 2010-10-14 2012-04-19 주식회사 프로셀제약 세포투과성 parkin 재조합 단백질 및 이를 함유하는 퇴행성 뇌질환 치료용 약학적 조성물
US9283287B2 (en) * 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2898326C (en) * 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
IL278213B2 (en) * 2018-04-27 2026-04-01 Rocket Pharmaceuticals Ltd A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)

Similar Documents

Publication Publication Date Title
AU2020203358A1 (en) Novel micro-dystrophins and related methods of use
JP2021531752A5 (enExample)
JP2023518596A5 (enExample)
JP2022520232A5 (enExample)
JP2022531861A5 (enExample)
JP2022520232A (ja) ダノン病の治療のための遺伝子療法ベクター
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP2006502702A5 (enExample)
RU2019103488A (ru) Способы и композиции для лечения нарушений и заболеваний, связанных с rdh12
JP2019524090A5 (enExample)
TW202227476A (zh) 編碼GJB2之重組腺相關病毒(rAAV)及其用途
JP2022542294A5 (enExample)
KR20230150836A (ko) 파브리병 치료를 위한 조성물 및 방법
JP2020517268A5 (enExample)
JP2022530068A5 (enExample)
KR20230029624A (ko) 유전자 치료를 위한 글루코스-6-포스파타제(G6Pase-a)를 코딩하는 벡터
JP2024528997A (ja) 放射線誘発性唾液機能低下を予防するためのaqp1遺伝子療法
JP2022530359A5 (enExample)
JP2024542023A5 (enExample)
US20190367564A1 (en) Compositions and methods for use of anion channel rhodopsins
CN111093716B (zh) 用于治疗神经性疼痛的方法和组合物
JP2023545384A5 (enExample)
CN116997657A (zh) 编码GJB2的重组腺相关病毒(rAAV)及其用途
JP7777905B2 (ja) 4rタウオパチーの治療または予防用ペプチド
RU2815545C2 (ru) Генная терапия гипофосфатемических заболеваний, связанных с фактором роста фибробластов 23